NewslettersPulmonary Cell News Alectinib Approved as an Adjuvant Treatment for Lung Cancer By Noshin Noorjahan - May 9, 2024 0 Based on the ALINA trial results, the FDA approved alectinib as adjuvant therapy for people with ALK-positive NSCLC. [National Cancer Institute] Press Release